Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
AssigneeBristol-Myers Squibb Company
InventorsMary STRUTHERS, Jonathan Harry DAVIS, Michael Louis DOYLE, Priyanka Apurva MADIA
Life of this patent
Estimating the term…
Abstract
Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
Claims32
A fusion protein comprising:
- (a) a first polypeptide comprising an Interleukin-2 (IL2) polypeptide, wherein the first polypeptide comprises an amino acid sequence having at least about 85% sequence identity to an amino acid sequence as set forth in SEQ ID NO:
- 102-115;
- and
- (b) a second polypeptide comprising an extracellular domain of an Interleukin-2 Receptor alpha (IL2Rα) polypeptide, wherein the second polypeptide comprises an amino acid sequence having at least about 90% sequence identity to an amino acid sequence as set forth in SEQ ID NO:
- 138-142;
- and
- wherein the fusion protein has IL2 activity.
2-3. (canceled)
6-14. (canceled)
16-53. (canceled)
55-57. (canceled)
(canceled)
62-64. (canceled)
67-71. (canceled)
73-79. (canceled)
83-87. (canceled)
91-95. (canceled)
97-109. (canceled)
111-114. (canceled)
Dependencies are inferred from the claim text.